Abstract
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder of the elderly characterized by learning and memory impairment. Stress level glucocorticoids (GCs) and β-amyloid (Aβ) peptide deposition are found to be correlated with dementia progression in patients with AD. The astragalosides (AST) was extracted from traditional Chinese herb Astragalus membranaceous. In this study, 12months male rats were treated with Aβ25–35 (10μg/rat, hippocampal CA1 injection) and dexamethasone (DEX, 1.5mg/kg, ig) and AST (8, 16 and 32mg/kg, ig) or ginsenoside Rg1 (Rg1, 5mg/kg, ig) for 14days. We investigated the protective effect of AST against DEX+Aβ25–35 injury in rats and its mechanisms of action. Our results indicate that DEX+Aβ25–35 can induce learning and memory impairments and increase APP and Aβ1–40 expression. AST (16, 32mg/kg) or Rg1 (5mg/kg) treatment significantly improve learning and memory, down-regulate the mRNA levels of APP and β-secretase, decrease expression of APP and Aβ1–40 in hippocampus. The results indicated that DEX might increase hippocampal vulnerability to Aβ25–35 and highlight the potential neuronal protection of AST.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.